XML 42 R31.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:

			Three Months Ended September 30,
			2025						2024
Revenue from collaborative arrangement			$	—					$	—
Less:
Research and development:
INO-3107			3,352,458						7,009,169
INO-3112 and other Immuno-oncology			1,574,238						1,726,382
Other programs (a)			96,971						(1,119,600)
Engineering and device-related			4,323,775						5,602,688
Stock-based compensation			302,249						590,211
Other unallocated expenses			3,683,638						4,924,734
General and administrative			7,877,126						8,613,895
Total operating expenses			21,210,455						27,347,479
Interest income			552,108						1,106,758
Change in fair value of common stock warrant liabilities			(22,515,730)						—
(Loss) gain on investment in affiliated entity			(589,618)						324,251
Net unrealized gain on available-for-sale equity securities			205,259						1,330,811
Other expense, net			(1,938,236)						(579,819)
Net loss			$	(45,496,672)					$	(25,165,478)

			Nine Months Ended September 30,
			2025						2024
Revenue from collaborative arrangement			$	65,343					$	100,762
Less:
Research and development:
INO-3107			10,790,120						25,697,828
INO-3112 and other Immuno-oncology			4,327,081						5,309,964
Other programs (a)			357,884						(292,372)
Engineering and device-related			14,470,247						14,192,615
Stock-based compensation			1,177,331						2,240,800
Other unallocated expenses			12,822,975						15,586,056
General and administrative			25,465,208						29,395,232
Total operating expenses			69,410,846						92,130,123
Interest income			1,970,823						3,914,406
Interest expense			—						(177,833)
Change in fair value of common stock warrant liabilities			(20,680,868)						—
Gain (loss) on investment in affiliated entity			881,886						(136,061)
Net unrealized gain on available-for-sale equity securities			1,104,782						1,810,868
Other expense, net			(2,641,901)						(1,254,466)
Net loss			$	(88,710,781)					$	(87,872,447)

(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration